Modified tPA could be effective stroke treatment without bleeding risk

July 17, 2012

Even when its clot-dissolving powers are removed, the stroke drug tPA can still protect brain cells from the loss of oxygen and glucose induced by a stroke, researchers have discovered.

The finding suggests that a modified version of could provide benefits to patients who have experienced a stroke, without increasing the risk of bleeding.

The results will be published in the .

"We may have been giving the right medication, for the wrong reason," says senior author Manuel Yepes, MD, associate professor of neurology at Emory University School of Medicine. "tPA is more than a clot-busting drug, it functions naturally as a neuroprotectant,"

The co-first authors of the paper are postdoctoral fellows Fang Wu and Jialing Wu from the Department of Neurology, and Andrew Nicholson from the Department of Radiology and Imaging Sciences.

tPA was introduced as a treatment for in the 1990s. Doctors have debated its effectiveness and safety ever since, because it can increase the likelihood of deadly . Many people experiencing a stroke do not receive tPA because of or other contraindications.

"tPA is supposed to be administered within the first 3-4.5 hours of the onset of the stroke," Yepes says. "Otherwise there is no beneficial effect and instead there is an increase in the risk of hemorrhagic transformation."

Long before tPA ever became a drug, tPA was a protein produced by several tissues in the body, including . One of its functions is to convert the inactive protein plasminogen into the enzyme plasmin, which breaks down clots. Yepes' team has been studying tPA's additional functions beyond acting on plasminogen.

Exposing from the to tPA protects the neurons from dying after being deprived of oxygen and glucose, the researchers found. tPA appears to induce a set of proteins that helps cells deal with the and glucose that come from an interruption of blood flow.

This result contradicts previous reports about tPA's effects in the nervous system, some of which concluded that it can act as a neurotoxin.

"The discrepancy could be a matter of experimental design or dose," Yepes says. "Our results do suggest that the dose of tPA that is needed for a neuroprotective effect is significantly lower that the dose that we give to destroy the clot in our stroke patients."

A mutated form of tPA that could not activate plasminogen still had the protective effect on neurons in culture. Yepes' team also studied the effects of the mutated form of tPA in living animals. In mice, the researchers blocked a vessel supplying blood to the brain for one hour, simulating a stroke. Treatment with both regular and modified tPA could reduce the size of the damaged area of the brain.

The possibility that tPA may be working as a neuroprotectant also may explain why, clinically, tPA's benefits are sometimes not observed until several weeks after treatment as it has been demonstrated in large clinical studies, Yepes says.

"If it was just a matter of the clot, getting rid of the clot should make the patient better quickly," he says. "It's been difficult to explain why you should have to wait three months to see a benefit."

"One of the main implications of our finding is that a form of tPA that does not act on plasminogen could still provide benefits, without the risks of inducing a bleeding in the brain," Yepes says. "The risk of bleeding creates a lot of anxiety, and it has resulted in the regrettable fact that only a small number of patients currently benefit from treatment with tPA."

Yepes says a next step would be to try a "protease-inactive" version of tPA in a pilot clinical trial.

Explore further: Clot-busting drug safe for stroke patients taking blood thinner

More information: F. Wu et al. Tissue-type plasminogen activator regulates the neuronal uptake of glucose in the ischemic brain. J. Neurosci (2012).

Related Stories

Clot-busting drug safe for stroke patients taking blood thinner

May 10, 2012
Acute ischemic stroke patients taking the blood thinner warfarin can be treated safely with the clot-busting drug tissue plasminogen activator (tPA), according to research presented at the American Heart Association's Quality ...

Hypothermia protects the brain against damage during stroke

March 6, 2012
Thromboembolic stroke, caused by a blood clot in the brain, results in damage to the parts of the brain starved of oxygen. Breaking up the clot with tissue plasminogen activator (tPA) reduces the amount of damage, however, ...

New clue to brain bleeding after stroke treatment

October 17, 2011
The only medication currently approved for stroke treatment – tissue plasminogen activator (tPA), which dissolves blood clots – is associated with an increased risk of bleeding in the brain, particularly among patients ...

Recommended for you

New map may lead to drug development for complex brain disorders, researcher says

July 24, 2017
Just as parents are not the root of all their children's problems, a single gene mutation can't be blamed for complex brain disorders like autism, according to a Keck School of Medicine of USC neuroscientist.

Bird songs provide insight into how developing brain forms memories

July 24, 2017
Researchers at the University of Chicago have demonstrated, for the first time, that a key protein complex in the brain is linked to the ability of young animals to learn behavioral patterns from adults.

Brain stimulation may improve cognitive performance in people with schizophrenia

July 24, 2017
Brain stimulation could be used to treat cognitive deficits frequently associated with schizophrenia, according to a new study from King's College London.

Scientists capture first image of major brain receptor in action

July 24, 2017
Columbia University Medical Center (CUMC) researchers have captured the first three-dimensional snapshots of the AMPA-subtype glutamate receptor in action. The receptor, which regulates most electrical signaling in the brain, ...

Research identifies new brain death pathway in Alzheimer's disease

July 24, 2017
Alzheimer's disease tragically ravages the brains, memories and ultimately, personalities of its victims. Now affecting 5 million Americans, Alzheimer's disease is the sixth leading cause of death in the U.S., and a cure ...

Illuminating neural pathways in the living brain

July 24, 2017
Using light alone, scientists from the Max Planck Institute of Neurobiology in Martinsried are now able to reveal pairs or chains of functionally connected neurons under the microscope. The new optogenetic method, named Optobow, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.